Evidence MultiSTAT™ Multiplex Immunoassay Analyzer
A compact, fully automated multiplex immunoassay analyzer using Biochip Array Technology for rapid detection of multiple analytes from a single sample. Supports high-throughput drug testing and clinical diagnostics with a simple cartridge-based workflow and results in under 30 minutes.
The Randox Evidence MultiSTAT multiplex immunoassay analyzer
Randox Evidence MultiSTAT multiplex immunoassay analyzer with pre‑filled biochip cartridge for rapid clinical drug testing
Receive your quote directly from the manufacturer.
Streamline clinical drug testing and multiplex immunoassay workflows with the Evidence MultiSTAT, a compact, fully automated platform powered by Randox Biochip Array Technology. Designed for modern laboratory environments, the system enables simultaneous detection of up to 48 analytes from a single patient sample, delivering rapid results in under 30 minutes with minimal preparation and hands-on time. Its cartridge-based, contamination-controlled workflow supports consistent, reliable performance across clinical toxicology, immunoassay, and critical care applications.
Drug testing and clinical toxicology
The Evidence MultiSTAT supports rapid, multiplex detection of drugs of abuse and prescription medications, with panels capable of identifying up to 29 classical, prescription, and synthetic drugs from a single urine sample. Fast turnaround times and simple three-step operation enable efficient screening in clinical and near-patient settings, supporting timely decision-making in emergency and critical care environments.
Multiplex immunoassay capability
Using patented Biochip Array Technology, the system performs simultaneous multi-analyte detection from a single sample, improving laboratory efficiency while reducing sample volume requirements. This capability supports a wide range of diagnostic applications, including clinical immunoassay and critical care testing.
Automated workflow and ease of use
The fully automated, cartridge-based design minimises manual handling and reduces the risk of contamination or operator error. The pre-filled MultiSTAT cartridge contains all reagents required for the chemiluminescent reaction and incorporates dedicated biochip wells for patient samples, simplifying assay setup. Combined with intuitive touchscreen operation and minimal maintenance requirements, the system is well suited to routine laboratory use, even in space-limited environments.
Compact and reliable operation
With a small footprint and low maintenance design, the Evidence MultiSTAT is well suited to decentralised and high-demand laboratory settings. Rapid sample-to-result workflows help reduce backlog and support improved patient pathways by delivering results quickly and reliably.
TechTalk: Taming the cytokine storm with near-patient immunoassay technology
Friday, August 14 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
A cytokine storm, or systemic hyperinflammation, is a life-threatening overreaction of the immune system that can rapidly drive organ failure, prolonged intensive care unit (ICU) stays and increased mortality. In critical care settings, early identification and intervention are essential, yet detecting and managing these complex inflammatory responses remains a significant clinical challenge.
Join this expert-led SelectScience® TechTalk to explore the challenges associated with cytokine storm detection and management in critical care settings. Learn about the latest approaches to anti-inflammatory interventions, strategies for identifying patients most likely to benefit from treatment, and the growing need for rapid diagnostic insights to support timely clinical decision-making in the ICU.
At the centre of this discussion is the Randox Evidence MultiSTAT™ immunoassay platform, a near-patient testing solution designed to deliver rapid inflammatory biomarker results when they matter most. Discover how MultiSTAT is helping to address gaps in current patient management by providing actionable data closer to the patient, with the potential to support patient stratification, streamline care pathways, and improve the balance between clinical outcomes and healthcare costs.
Presented by Dr. Scott McKeown, a Near Patient Diagnostics Manager with a published research background in chronic inflammation, respiratory disease and cancer, this session combines real-world clinical insight with expertise in the technologies shaping the future of critical care diagnostics.
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available
Randox receives FDA 510(K) clearance for clinical drug testing device
New drug testing panel supports rapid, automated screening of 15 drugs of abuse in clinical and critical care settings
